Introduction
============

Vitamin D and Calcitriol
------------------------

Two types of vitamin D molecules exist: vitamin D~3~(cholecalciferol), which is animal-derived; and the plant derived vitamin D~2.~Vitamin D~3~ is a steroid-like molecule, which is considered to be a prohormone and is the predominant form of vitamin D in humans[@B1]. It can be endogenously synthesized from sterol 7-dehydrocholesterol in the skin through exposure to ultraviolet B radiation. Alternatively, vitamin D, in the form of either vitamin D~3~ or D~2~, can be acquired from the diet or dietary supplements. Vitamin D, either as D~3~ or D~2~, requires a two-step activation process to become biologically active[@B1]. Vitamin D~3~ is highly lipophilic that is transported in the blood stream only when bound to a specific plasma protein called vitamin D-binding globulin (VDBP). It is taken up within hours following synthesis or dietary uptake to be activated by liver and kidney[@B2]. In the liver, where multiple cytochrome P450 (CYP) enzymes are present, mitochondrial CYP27A1, microsomal CYP2J3 and CYP2R1 are readily available and capable of hydroxylating vitamin D~3~ at the C-25 position to form 25(OH)D~3~, which is then released into the blood stream for further activation, primarily in the kidney[@B3],[@B4]. Serum 25(OH)D~3~ is often considered an acceptable measurement of vitamin D~3~ levels in the body[@B5]. It has a short plasma half-life and a long systemic half-life of \~6 hours and \~ 2 months, respectively[@B2],[@B6]~.~ When serum calcium levels are low, renal CYP27B1 converts 25(OH)D~3~ to 1, 25 dihydroxyvitamin D~3~ (1, 25(OH)~2~D~3~; calcitriol). Calcitriol is the most active form that exists as a small lipophilic molecule with superior cellular penetration[@B5] (**Figure [1](#F1){ref-type="fig"}**).

Traditionally, most of the randomized clinical trials (RCT) have focused on bone mineralisation and fracture risk that associated to serum vitamin D levels[@B7]. Numerous epidemiological studies recently have shown that low serum levels of vitamin D~3~ increases the risk of developing cancers of the colon, ovary, lung breast and prostate[@B4],[@B8]-[@B12]. However, there have been mixed results from clinical studies with respect to their promise of cancer chemoprevention and/or treatment with vitamin D and we are yet to see compelling evidence that the numerous published preclinical studies may actually be translated to humans and cancer patients[@B13],[@B14]. The most favorable benefits observed for vitamin D intake have been documented with respect to the inverse relationship between serum levels seen in patients with colon and breast cancer[@B14]. For prostate and skin cancer, however, inverse associations between cancer risk and serum vitamin D levels in clinical trial has been difficult to demonstrate so far[@B14]. Consequently, we are limited in our ability to provide guidelines for vitamin D intake, which serve as a model to define optimal levels of serum 25(OH)D~3~ that protect against the development of cancer[@B4]. Report from the U.S. Institute of Medicine (IOM) suggests that serum levels greater than 20 ng/mL are recommended that could offer optimal health benefits[@B4],[@B7],[@B11],[@B15],[@B16]. It is possible that, for individuals with limited sun exposure, these levels are achievable by taking vitamin D~3~ supplements daily in the range of 1000-4000 IU.

Calcitriol plays an important role in mineral homeostasis and bone growth by promoting the export of calcium from bone, absorption of calcium from the gastrointestinal tract and the stimulation of the absorption of phosphate and magnesium ions to support mineralization. It works as both a paracrine and an autocrine agent by binding to intracellular vitamin D receptor (VDR) to form a complex with the retinoid-X receptor. The resulting heterodimer binds to DNA to function as a transcription factor to either initiate or suppress gene expression[@B17],[@B18]. The VDR has a higher affinity towards calcitriol than any other form of vitamin D, which explains its relatively high biological potency[@B19]. Besides calcitriol, various steroidal and non-steroidal synthetic analogs, non-vitamin D related endogenous compounds (e.g. lithocholic and arachidonic acid) and dietary ligands including curcumin and fatty acid derivatives, are also capable of activating VDR[@B20],[@B21]. VDR is present in moderate levels in most cells in the body including the kidney, heart, muscle, breast, colon, prostate, brain and immune cells[@B17]. The gastrointestinal tract and bone are the two sites where VDR is highly expressed and consequently are the primary targets of calcitriol-mediated physiological effects[@B4]. Calcitriol has potent effects on factors involved in growth and differentiation of many types of cancer cells, as well as cell adhesion and apoptosis. This could be largely due to its role in regulating the cell cycle and number of genes that are implicated in cancer initiation[@B4]. Calcitriol has been shown to exhibit anti-proliferative, pro-differentiating, pro-apoptotic and anti-inflammatory actions in a variety of cancer cells in vitro including PCa cells [@B22]-[@B24]**(Figure [2](#F2){ref-type="fig"})**.

Calcitriol bioavailability in tissues is largely determined by its affinity to bind to the VDBP plasma transporter, rate of synthesis from 25(OH)D~3~ and rate of degradation by catabolizing enzymes. When calcitriol is administered orally, it is absorbed rapidly with approximately 99.9% bound to and transported via VDBP in the blood and a serum half-life of approximately 15 hours[@B25],[@B26]. Calcitriol levels in the blood depend largely on its bioavailability, ratio of binding to plasma and tissue proteins, perhaps also its binding to lipoprotein as well as the equilibrium that exists for its biosynthesis from 25(OH)D~3~ and catabolic degradation steps in the kidney and liver, respectively. Within tissues, its levels are reflective of both blood 25(OH)D~3~ and 1, 25(OH)~2~D~3~ free levels as well as the balance between the local biosynthesis from 25(OH)D~3~ and its rate of degradation[@B27].

Prostate cancer
---------------

PCa is the most commonly diagnosed cancer among old men worldwide and the third leading cause of cancer-related deaths in Canada after lung and colorectal cancers[@B14],[@B28]-[@B31]. To effectively manage the disease and eventually develop novel cancer therapeutics that improve prognosis of PCa, better understanding of the different molecular mechanisms that occur during PCa initiation and progression is necessary. Prostate-specific antigen (PSA), which serves as a biomarker for PCa, has made it possible to detect the disease at the early stages and render better prediction of its behavior. However, there has been considerable debate about the benefits of screening patients using PSA due to limitations in its clinical use in predicting the outcome or response to therapy. PSA lacks specificity for PCa because as it is unable to distinguish well between benign prostatic hyperplasia and malignancy. This perhaps could lead to either over-treatment or unnecessary tissue biopsies[@B32],[@B33]. There has been a great deal of efforts invested in searching for novels biomarkers in serum, urine and tissue but few presented with the ability to replace PSA[@B33].

Initiation and progression of PCa are characterized by alterations in regulatory pathways of apoptosis, androgen receptor (AR) signaling, cell cycle regulation, signal transduction, cell adhesion and cohesion, and angiogenesis, which may occur within the prostate cells and/or the surrounding tissues. Disruption of these pathways leads to unregulated proliferation of the damaged cells and subsequent accumulation of mutations, resulting in malignancy. Examples of potential candidate markers of prognosis and therapeutic response involving these pathways include p53 and Bcl-2, AR, p27, p21 and CDK, Ki-67, retinoblastoma protein pRb and c-Myc, epidermal growth factor (EGF) receptor family and E-cadherin, vascular endothelial growth factor (VEGF), respectively[@B32],[@B34].

AR signaling pathways play a significant role in the early development of PCa, as well as in the advanced stages of the disease where the prostate is androgen-independent that fails to respond to hormone deprivation therapy. PCa is initially dependent on androgens, mainly testosterone or dihydrotestosterone (DHT), which activate the AR to transcriptionally regulate the expression of multiple genes including PSA. Androgens play a critical role in disease progression and are required for the growth and survival of castrate-sensitive as well as castration-resistant PCa (CRPC) cells. In addition, PCa cells are capable to grow even when the androgen levels are low due to de novo synthesis of androgen[@B35]. The majority of men with PCa eventually advance to an androgen-independent stage and become refractory after about two years with an increased PSA and/or symptomatic progression[@B36]. Nevertheless, chemotherapeutic agents seem to have little or no impact on the survival of such patients. Most patients who die from PCa have hormone refractory disease. While many PCas still express AR, only about 30% of the patients respond to anti-androgen therapy that prevents androgens from binding to AR to achieve complete androgen blockade[@B37], thus indicating the development of CRPC. Several mechanisms of CRPC progression have been proposed: mutations in the AR resulting in amplification of the AR and emergence of AR splice variants, changes in the activity of AR coregulators or pathways other than AR-mediated pathways are involved[@B38]. Studies have also shown that CRPC development triggers a release from the arrest resulting in cell cycle progression, even in the absence of androgens. Furthermore, epidermal growth factor (EGF), insulin-like growth factor (IGF), keratinocyte growth factor (KGF) and cytokines interleukin-4 and -6 have also been demonstrated to activate AR[@B39]-[@B42].

To date, therapeutic options for CRPC are limited. No particular class of chemotherapeutic drugs are considered highly effective. Among the existing therapeutics, docetaxel is currently considered to be the gold standard which demonstrates an increase in survival of only 3 to 4 months with considerable associated morbidity[@B43]-[@B46]. New therapeutic approaches are being explored. Agents with growth inhibitory properties that work independent of the androgen pathways are also of current interest.

Calcitriol in Prostate cancer
-----------------------------

The vitamin D derivatives are currently being used in the treatment of many diseases such as psoriasis and vitiligo[@B47]. However, there is a limitation in the broader use of calcitriol as a single anticancer agent clinically due to its toxicity at higher doses. Calcitriol has limited bioavailability at the tumor site which is actively confounded by local CYP-mediated deactivation[@B5]. Since dose elevation constraints exist due to its hypercalcemic side effects, to achieve desired clinical outcomes in cancer patients, the pharmacological doses required often lead to an extreme elevated plasma levels of calcium and phosphorus and cause adverse hypercalcemia and hypercalcaemia effects[@B5].

It has been reported that VDR is expressed in three human prostate carcinoma cell lines; LNCaP, PC-3, and DU-145 as well as in the primary culture of stromal and epithelial cells derived from normal and malignant prostate tissues[@B48]. Many preclinical studies have been quite consistent in their demonstration of exposure to high calcitriol concentrations resulting in inhibition of PCa cell growth in vitro and retardation or slow-down of tumor growth in animal models of PCa[@B49]. Pre-clinical studies demonstrated that 10 nM (4.2 ng/ml) concentrations of calcitriol are associated with anticancer activity in vitro and in vivo[@B50],[@B51]. Pharmacokinetic (PK) studies in normal mice indicate that calcitriol, at a dose of 0.125 µg/mouse, is able to suppress tumor growth and results in a peak plasma calcitriol concentrations (Cmax) of 12 ng/ml with corresponding areas under the curve from time 0 to 24 hr of 47 ng•h/ml. Calcitriol anticancer activity is mainly dependent on its dose, and its serum concentration ranges escalate from 0.5 to 41 ng/ml, resulting in significant toxicity[@B52],[@B53]. There have been many approaches taken to elevate tumor calcitriol levels that have been reported in the literature, making it feasible to see anticancer benefits while limiting its toxicity. Specifically, calcitriol may be administered on an intermittent schedule, analogues with low/no calcemic activity may be substituted, and using calcitriol in combination with other agents could enhance anticancer activity and allow for lower calcitriol doses to be optimised[@B50].

Calcitriol in combination therapy for PCa
-----------------------------------------

Monotherapy has limited efficacy in cancer prevention and is mostly ineffective in curing cancers because of the heterogeneous pathways which contribute to their occurrence. In recent years, new drugs and drug combinations have contributed to improvements in treatment outcomes of PCa[@B54]. Combination regimens of chemotherapeutic drugs were developed in the 1960s and early 1970s, based on observations that single drug administration at clinically tolerable dosages failed to cure cancer as normal tissue toxicity often limits the use of a single agent. Combination therapy offers significant benefits when compared to single-agent therapy by providing: (i) maximal cell kill within the range of tolerable toxicity by allowing lower drug doses; (ii) diverse interactions between the drugs procuring pleiotropic effects which may be optimal for treating a heterogeneous tumour; (iii) the potential to prevent or slow the subsequent development of cellular drug resistance as combined drugs work by different mechanisms; (iv) lower cost incurred as lower doses or/and less frequent drug administration is required; (v) reduced side effects of individual drugs because each drug can be used optimally at a lower dose; (vi) better clinical outcomes when the approach take is not curative but intended to reduce symptoms and prolong life.

Optimal drug combination effects are likely to be achieved when combined drugs have different mechanisms of action and no overlapping toxicities. Individual drugs which are used in combination should be partially effective against the same tumor type. In addition, PK and pharmacodynamic (PD) interactions could occur as a result of combining drugs and should therefore also be investigated at the onset. These interactions can be either beneficial by allowing a therapeutic effect to be achieved with low doses of component interventions, which often minimizes potential side effects. Alternatively, they can exist as problematic antagonistic interactions when combined pharmacological outcomes lead to unwanted, toxic and result in lower effectiveness than expected from the individual activities of the combined drugs. Drug combinations that interact in a manner that results in additive or synergistic effects, where the combined effects exceed that anticipated based on the effects of the individual agents are ideal and therefore of great interest.

Concurrent administration of a lower dose of calcitriol and other anticancer drugs may be the best option that helps to overcome this obstacle and lead to achieving the desired anticancer concentrations with low toxicity. The combination approach for calcitriol used recently with docetaxel in a clinical trial was successfully implemented and achieved the desired anticancer effect with no toxicity in PCa patients[@B55]. This study demonstrated that administration of calcitriol dose up to 45 μg/week combined with weekly i.v docetaxel led to Cmax values of 3.4 ± 0.8 nM (1.41 ± 0.33 ng/ml) and was not associated with any significant toxicity[@B55]. Other clinical studies suggest that the maximum tolerated dose (MTD) of i.v dose calcitriol in combination with gefitinib was 74 µg/week[@B26],[@B56]. The Cmax at the MTD was 6.68 ± 1.42 ng/mL (16 ± 3.4 nM) and the area under the curve (AUC) was 35.65 ± 8.01 ng h/mL. However, this reported Cmax was much higher than calcitriol concentrations considered to be required for antitumor activity as demonstrated in vitro[@B50],[@B51],[@B57].

The aim of this review is to summarize, the currently available preclinical and clinical studies with calcitriol used either alone or as part of a combination therapy approach to treat PCa. Articles for review were searched using PubMed using the keywords: vitamin D, calcitriol, 1, 25(OH)~2~D~3~ and PCa. In this review, we highlighted the major considerations for the use of calcitriol in combination therapy with respect to safety and factors that influence the PK/PD interactions and clinical outcomes.

Pharmacokinetic Based Interactions
==================================

When calcitriol is used in combination with other drugs, calcitriol-drug PK interactions have the potential to affect pharmacological outcome in several ways: (i) alteration of calcitriol serum and tissue concentrations, (ii) alteration of calcitriol hepatic metabolism due to induction or inhibition of hepatic enzymes, (iii) alteration of extrahepatic enzymes by induction or inhibition, and (iv) induction or inhibition of drug transporters that could interfere with calcitriol cellular uptake. Alterations in the synthesis (CYP27B1 mediated) and metabolism (mediated by CYP3A4 and CYP24A1) of calcitriol is modulated as part of the growth regulation of tumors; thus, compromising calcitriol potency and sensitivity. Overall, PK interaction outcomes can lead to the significant modification of calcitriol levels in both serum and tissues.

Calcitriol and CYP enzymes
--------------------------

CYP enzymes catalyze the synthesis and metabolism of a large number of endogenous substrates, including steroids, vitamins, fatty acids, prostaglandins and leukotrienes, as well as the detoxification of exogenous compounds, including drugs, environmental chemicals and pollutants, and natural plant products[@B58]-[@B60]. CYP monooxygenases are a major class of phase I metabolizing enzymes that acts either by adding or removing functional groups to/from substrates for further metabolism, thereby facilitating excretion of xenobiotics.

There are four CYP isoforms that participate in the synthesis and breakdown of calcitriol. CYP27A1 and CYP27B1, located in the mitochondria, are involved in the first steps of calcitriol synthesis from vitamin D~3~ and 25(OH)D~3~ is located in kidney and liver[@B3],[@B60]. Mechanisms of vitamin D metabolism within the prostate remain poorly understood. Historically, mitochondrial CYP24A1 has been reported to be the main enzymes responsible for 25(OH)D~3~ and a calcitriol metabolism. However, recently our lab and others have shown that CYP3A4, which is located in the endoplasmic reticulum, is a contributor to calcitriol degradation in vivo and in vitro[@B23],[@B61]-[@B63]. As shown in Figure [2](#F2){ref-type="fig"}, two metabolic pathways exist in the prostate; the first involves the 24-hydroxylase as the first-step in catabolism of calcitriol. There is strong data supporting 24-hydroxylase activity in the kidney; this enzyme is also present in many target tissues, such as the intestine, which possess vitamin D receptor. As depicted in Figure [2](#F2){ref-type="fig"}, the end product of this pathway is a side chain cleaved metabolite, calcitroic acid. The second pathway involves the conversion of calcitriol via stepwise hydroxylation of carbon-26 and carbon-23, and cyclization to ultimately yield 1α,25R(OH)~2~-26,23S-lactone D~3~ (Figure [2](#F2){ref-type="fig"}). In some instance mutations in certain CYP genes, have been suggested to play a role in PCa development and progression[@B64]. Specifically, mutations in CYP17 and SRD5A2 (encoding for 5α-reductase enzyme) genes have been reported to increase the risk of PCa and is found in some cases of hereditary PCa[@B34],[@B59],[@B64],[@B65]. Over-expression and mutations in CYP24A1 induce idiopathic infantile hypercalcemia which is linked to PCa resistance[@B66],[@B67]. Moreover, there is an association between polymorphisms in CYP3A4 and the increased risk of PCa in men with benign prostatic hyperplasia[@B59],[@B64],[@B68]. In general, changes in the DNA, RNA and/or protein levels, and the activities of the targets discussed above are found to significantly correlate with Gleason grade and may suggest PCa progression to an androgen-independent stage[@B34],[@B64]. Therefore, it is reasonable to suggest that CYP enzymes, such as CYP24A1, may be used as novel drug targets and also perhaps allow accurate prediction of tumor progression.

Combinations that affect calcitriol synthesis
---------------------------------------------

### Role of CYP27B1

Circulating serum levels of 1,25(OH)~2~D~3~ are tightly regulated by the renal enzyme, 25-hydroxyvitamin D-1α-hydroxylase, CYP27B1, which synthesizes calcitriol from the prohormone, 25(OH)D~3~. The renal production of calcitriol is tightly regulated by plasma parathyroid hormone (PTH) levels and serum calcium and phosphorus levels[@B69]. In response to low calcium levels, PTH levels rise up and regulate the expression of CYP27B1 leading to the synthesis of calcitriol, which is then released into plasma to serve its endocrine function to maintain calcium homeostasis and bone metabolism.

Many cell types, including prostate cells, immune cells, cells of the gastrointestinal tract, brain cells, and importantly skin cells are capable of calcitriol production. Thus, they can provide hormone for local signaling which could also explain the wide distribution of the and VDR in these organs[@B70]. In prostate cells, since they contain VDR, an additional role of calcitriol as an autocrine/ paracrine regulator of cell functions could be expected[@B5]. It has been reported that primary cultures of normal prostate epithelial cells, as well as several PCa cell lines, express CYP27B1 and can synthesize the active hormone calcitriol intracellularly[@B48],[@B70]. In addition, the CYP27B1 activity declines in BPH and PCa cells compared to the normal prostate cells[@B71]. In vitro studies using high performance liquid chromatography (HPLC) to measure calcitriol in the media have demonstrated that two PCa cell lines (DU145 and PC3, but not LNCaP) and normal prostate cells were able to produce calcitriol after cells were exposed to 25(OH)D~3~. In addition, in the presence of clotrimazole the ability of PCa cell lines, except LNCaP, to produce calcitriol was inhibited. These results correlated with an inhibition of CYP27B1 mRNA expression whereas no CYP27B1 mRNA or protein activity was detected in LNCaP cells, which may contribute to the resistance[@B48],[@B70].

It has been reported that the control of calcitriol synthesis in tissues like bone and prostate is distinct in which calcitriol levels potentially fall earlier in these tissues than in the plasma[@B17]. In vitro studies suggest that the prostate CYP27B1 enzyme is not regulated by serum levels of PTH and calcium compared to the renal enzyme. This supports the hypothesis that extrarenal administration of vitamin D may be useful as a chemopreventive agent, and that calcitriol should be synthesized from 25(OH)D~3~ locally within prostate cells[@B72],[@B73]. However, a recent study in mouse prostate xenograft model has demonstrated that dietary vitamin D~3~ administration caused an increase in serum calcitriol levels without causing any alteration in kidney CYP27B1 mRNA[@B74]. In addition, both dietary vitamin D~3~ and calcitriol imparted equivalent reductions in tumor volume in this xenograft model. This hypothesis was also tested clinically and calcitriol prostate levels were shown to increase significantly after oral administration of vitamin D supplements[@B27]. These results suggest that extra renal sources of vitamin D and local synthesis within prostate do, in fact, contribute to the elevated circulating calcitriol. No studies have been reported to date which examine the effect of drugs combined with calcitriol and their impact on CYP27A1 expression or how it affects calcitriol levels within the prostate.

Combinations that inhibit calcitriol metabolism
-----------------------------------------------

### Role of CYP24A1

CYP24A1 recognizes 25(OH)D~3~ as a substrate and can mediate its hydroxylation to the active metabolite, calcitriol [@B5]. This enzyme also recognizes other vitamin D metabolites and analogs and actively converts them to their hydroxylated products[@B5],[@B75]. CYP24A1 is also responsible for calcitriol metabolism, mainly in the kidney but also in a variety of other vitamin D target cells. It converts it to water-soluble calcitroic acid which is then conjugated and excreted in bile[@B1],[@B76]. The cyp24a -knockout mice studies have confirmed the physiological role of CYP24A1 in 25(OH)D~3~ and calcitriol hemostasis as a build-up of vitamin D~3~ was observed in the knockout mouse phenotype[@B76],[@B77].

CYP24A1 is highly expressed in the kidney but is also present in other normal tissues such as the prostate[@B78]. Calcitriol can also induce CYP24A1 and its own metabolism, thus has the capacity to limit its physiological functions. The levels of CYP24A1 expression may reflect the endocrine and autocrine/paracrine effects of vitamin D~3~ in the human body. CYP24A1 overexpression is a common feature of several solid tumors and was detected in a wide range of cancers such as breast, prostate, skin, esophagus, and gastrointestinal tract cancers[@B67],[@B79]. It can contribute to the pathology of diseases that otherwise would respond to endogenous or supplemented vitamin D sources and it is associated with poor prognosis due to rapid degradation of both 25(OH)D~3~ and calcitriol, limiting their levels in the tumor cells and thus abrogating local anti-cancer effects of calcitriol [@B27],[@B80]~.~

Administration of calcitriol in combination with CYP24A1 inhibitors slows its catabolism, thereby enhancing its antitumor activity and antiproliferative effect (Table [1](#T1){ref-type="table"}). Following treatment of DU145 PCa cells for 4 days with 1 µM liarozole, which is an imidazole derivative known to inhibit CYP enzymes, in combination with 10 nM calcitriol, the inhibitory effect on cell viability was further enhanced almost by 65% compared with no significant effect seen with either treatment alone. It is likely that this effect was mediated by inhibiting CYP24A1 activity, which resulted in a significant increase in calcitriol half-life from 11 to 31 h, thus enhancing the calcitriol anticancer activity. The combination treatments also led to greater VDR upregulation than cells treated with either drug alone[@B81]. A recent study reported that protein kinase CK2 positively regulates CYP24A1 expression and mediates the regulation of its expression. In keeping with this, inhibition of CK2 activity has been shown to cause a reduction in PCa cell proliferation and enhance calcitriol -mediated antitumor effect[@B82].

In vitro treatment of PC3 cells with calcitriol in combination with ketoconazole or RC2204 (a selective inhibitor of CYP24A1) acted synergistically by potentiating calcitriol-mediated antiproliferative effects, promoting the activation of caspase-independent apoptosis pathways. However, ketoconazole is a well-known non-selective inhibitor of CYP enzymes and dexamethasone (potent anti-inflammatory agent used routinely in the chemotherapeutic regimen) was added that has the ability to induce CYP and up-regulate VDR protein expression and activities in vitro[@B83],[@B84]. Thus, conclusions deduced following this observation are limited as they are confounded by the contribution of other mechanisms. The authors proposed that potentially ketoconazole inhibit the CYP24A1-mediated oxidative metabolism of calcitriol leading to increase in half-life and systemic exposure previously observed in PC3 cells and C3H/HeJ mouse kidney tissues. These observations were confirmed in vivo when the calcitriol and ketoconazole-dexamethasone combination therapy suppressed the clonogenic survival and enhanced growth inhibition observed with calcitriol treatment alone in the PC3 human PCa xenograft mouse model[@B51].

### Role of CYP3A4

CYP3A4 is a major hepatic phase I oxidative drug-metabolizing enzyme. It has broad substrate specificity and is inducible after exposure to therapeutic, dietary, and environmental agents [@B85]. Variability in CYP3A4 activity accounts for large interindividual differences in the disposition if endogenous, xenobiotic and therapeutic drugs[@B68]. CYP3A4 polymorphisms could contribute specifically to potential inter-individual and interethnic variation in steroid metabolism as it is characteristically involved in the oxidative metabolism of testosterone, thus mediating prostate cell growth. Consequently, CYP3A4 function may play a role in androgen-mediated prostate carcinogenesis if the bioavailability of testosterone is affected[@B68]. CYP3A4 is expressed in many organs including prostate, breast, gut, colon, and small intestine; however, its expression is most abundant in the human liver, accounting for 30 percent of the total hepatic CYP protein content[@B86]-[@B88]. CYP3A4 is also highly expressed in intestine but with remarkably different composition and abundance than the liver. The intestinal CYP system is mainly comprised of CYP3A enzymes (82%)[@B87]. However, the total amount of intestinal CYP3A protein is only approximately 1% of that in liver[@B87]. It exhibits a broad substrate specificity and is responsible for oxidation of many therapeutic drugs and a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. It can also be inhibited by a variety compounds including drugs, nutrients, and carcinogens, resulting in low CYP3A4 activity in all of the tissues in which it is expressed, including the prostate.

It has been previously shown that in human liver and intestine CYP3A4 is responsible for the oxidative metabolism of calcitriol[@B61],[@B89]. Specifically, CYP3A4 mediates 24- and 25-hydroxylation of calcitriol, but not vitamin D~3~, in human liver microsomes[@B90]. Using specific CYP chemical inhibitors we have reported that CYP3A isoforms are responsible for the microsomal biotransformation of calcitriol in liver and intestine in vitro[@B23]. Co-incubation of calcitriol with commonly used CYP3A4 substrates/drugs (e.g. ketoconazole, tamoxifen, ritonavir or clarithromycin) led to approximately 60-100% inhibition of CYP3A4-mediated inactivation of calcitriol in human liver and intestine microsomes[@B61]. In addition, recently we have shown that ginsenoside metabolites from ginseng herbs, mainly 20(S)-protopanaxadiol and 20(S)-protopanaxatriol, strongly inhibited CYP3A4 activity in vitro and could potentially therefore provide additional benefits to patients with cancer, neurodegenerative and metabolic diseases when used in combination with calcitriol[@B63]. Similarly, we have also reported that abiraterone, a CYP17A1-mediated steroidogenesis inhibitor used in late stage PCa treatment, inhibits the CYP3A4-mediated inactivation of calcitriol in human liver and intestine, potentially providing additional anti-cancer benefits to PCa patients[@B62]. In the context of PCa, the inhibition of CYP3A4 may lead to reduced ability of the enzyme to oxidize calcitriol in the liver and thus sparing calcitriol catabolism to yield higher intracellular levels. Therefore, the metabolism of calcitriol in the intestine and liver could contribute more to calcitriol bioavailability and tissue levels than CYP24A1[@B89]. The combination of calcitriol with CYP3A4 inhibitors, therefore, could allow for the use of lower doses of calcitriol and still achieve significant anticancer effects.

Pharmacodynamic Based Interaction
=================================

VDR and AR cross talk
---------------------

VDR is a nuclear receptor that binds calcitriol and regulates the transcription of target genes in the nucleus. VDR is universally expressed in both androgen-dependent and independent PCa cell lines which have differential sensitivity to calcitriol treatment[@B91]. Six PCa cell lines were reported to contain VDR mRNA and had high-affinity saturable binding sites for calcitriol[@B78]. Many factors regulate the amount of VDR in target cells that could potentially alter the magnitude of response to calcitriol exposure. Specific to the prostate, calcitriol response depends not only on absorption, transport into the circulation, plasma levels, ultimate prostate tissue levels and metabolism but also on intact VDR for signaling. The absence of intact VDR or loss of its function would decrease or eliminate the pharmacological responses to calcitriol in the prostate. A recent report that examined the expression of VDR protein in 841 PCa patients concluded that a high expression of VDR in prostate tumors is associated with a reduced risk of lethal cancer[@B92]. In addition, genetic predisposition is seen as a risk factor to prostate cancer, there are several studies suggesting the association between genetic variants in VDR and the development of PCa or likelihood of progression to an advanced stage[@B93]-[@B95]. Significant associations with five common genes (Fok1, Bsm1, Taq1 and ApaI), with high Gleason score have been reported with strongest evidence for Fok1 and Bsm1[@B94],[@B96].The expression of VDR could, therefore, be used to help improve prognostic prediction of PCa progression and guide treatment decisions for men. In addition, VDR polymorphisms should also be integrated as a prediagnostic indicator of vitamin D status[@B97].

PCa is known as an androgen-dependent malignancy and the fact that other hormones such as calcitriol are now recognized as modulators of PCa growth and differentiation, suggest a role for pharmacological agents, which might make use of this endocrine axis. There is now considerable evidence to suggest that cross-talk exists between VDR and AR that may vary between different PCa cell lines[@B98]. In addition, the phenomenon of sharing the same co-regulators which results in interdependence of AR and VDR signaling may contribute to the therapeutic activity of vitamin D in PCa[@B98],[@B99]. The AR belongs to the superfamily of steroid nuclear receptors. AR coregulators, which were originally identified as AR-associated proteins, can modulate many other steroid receptors in this super-family. Co-regulators can act to enhance (co-activate) or decrease (co-repress) the AR and changes in its expression have been shown to correlate with poor prognosis in PCa patients[@B38]. It has been reported that a large number of coregulators are overexpressed in PCa[@B100]. Several AR regulators, including ARA54, ARA70, gelsolin, and supervillin, have been reported to promote VDR[@B98]. Thus, by targeting this cross talk new therapeutic strategies designed to treat PCa could be developed.

Summary of preclinical studies
------------------------------

Several studies carried out in cell culture and animal models, as well as clinical trials, have shown that calcitriol pre-treatment or combination with other therapeutic agents provides anticancer benefits which are superior to treatment with either agent alone[@B101]. Calcitriol apparently sensitizes cancer cells, enhancing their antitumor activity, and can act synergistically with other therapeutic agents. Targeting multiple pathways or the same pathway through a different mechanism maximizes the likelihood of a therapeutic effect while limiting tissue toxicity (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

### Calcitriol combinations which sensitize PCa cells to anticancer drugs

Calcitriol has been shown to sensitize PCa to low temperature-induced, non-ice rupture-related cell death in vitro and in vivo. When calcitriol used with cryotherapy treatment, it significantly increased cell death and reducing cell viability via activation of apoptosis[@B44]. Calcitriol enhanced antitumor effect of cryoablation by increasing necrosis and apoptosis and reduced cell proliferation. Thus, calcitriol could potentially be an applicable reagent as a freeze sensitizer to cryoablation[@B1]. Radiotherapy, which is often a curative treatment option for PCa, however, also presents with a high risk of side effects at effective doses of ionizing radiation (IR). So when human androgen-insensitive DU145 PCa cells were pre-treated with a combination of 100 nM calcitriol and 1 mM sodium valproate, a well-tolerated histone deacetylase, led to sensitization of the PCa cells to IR[@B102]. This calcitriol pre-treatment with IR efficiently suppressed PCa cell proliferation and increased DNA double-strand breaks compared with non-pretreated cells. Combined pre-treatment of calcitriol with IR also resulted in 16 % enhancement in IR-induced activation of DNA damage CHEK2 compared to untreated cells. These molecular changes led to DNA replication blockade, S-phase cell cycle arrest and enhanced apoptosis. This combination approach could, therefore, be useful and allow for doses of radiation administered to cancer patients to be attenuated such that side effects are reduced[@B22],[@B103].

Calcitriol enhanced the anti-proliferative and the cytotoxic effects of taxanes chemotherapy (e.g., paclitaxel and docetaxel) in vitro when used in a combination treatment to treat PC3 cell lines[@B104]. This is thought to be due to its ability to reduce multidrug resistance-associated protein-1 expression and, therefore, inhibit transporter mediated efflux of docetaxel from cells[@B105]. Calcitriol also sensitizes PCa cells by inducing apoptosis and slowing cell cycle and cell proliferation. The growth of PCa cell lines (LNCaP and DU145) were inhibited when cells were treated with a platinum compound (cis- or carboplatin), and its synthetic analogue, Ro 25-6760. However, the growth inhibition was further enhanced by calcitriol. The enhancement of inhibitory effect was greater when lower concentrations of these compounds were used in combination with higher concentrations of calcitriol. At IC~20~ doses, calcitriol and a platinum compound acted in a synergistic manner to inhibit the growth of PC cells[@B106].

### Calcitriol Combinations which act additively or synergistically with other anticancer agents on PCa cells

Mitoxantrone combined with glucocorticoids has been widely used to treat androgen-independent PCa. Calcitriol synergistically increased mitoxantrone/dexamethasone mediated growth inhibition of PC-3 cells in vitro. The combination also caused significantly greater tumor regression in the PC-3 xenograft model system compared with treatment with mitoxantrone/dexamethasone or untreated controls[@B107].

There is increasing evidence that the isolation of a single compound from complex foods may not be effective in preventing cancer even when administered at toxic doses, whereas combination therapy using lower doses with no or lower toxicity might work. Genistein is a dietary-derived isoflavonoid found in high concentrations in serum after ingestion of soy-rich meals[@B108]. Studies reported that low concentrations of 0.5µM genistein tested in vitro in combination with 0.1 or 0.5 nM calcitriol was synergistic in the inhibition of primary human prostatic epithelial and LNCaP PCa cell viability. However, treatment of cells with genistein or calcitriol alone had no significant effect on cell viability. In primary cells, the combination acted synergistically as both resulted in G2/M and G1/0 cell-cycle arrest, whereas in LNCaP cells the combination had similar effects compared to treatment alone[@B109]. When concentrations higher than 5 µM genistein were used in combination with 10 nM calcitriol, up-regulation of cell cycle inhibitor p21 levels were seen compared to treatment alone and genistein potentiated the effect of calcitriol regulation of VDR expression.

Calcitriol and 20% dietary soy protein were also examined in vivo as a combination diet in a mouse xenograft model of PCa[@B110]. The combination diet resulted in a more substantial inhibition of tumor growth than treatment with either agent alone. Upon examination of the tumor tissue, it was deduced that potential mechanisms affected by combination treatment included up-regulation of several genes involved in prostate cell regulation such as anti-proliferative (p21, IGFBP-3) and pro-apoptotic (Bax) genes, down-regulating the anti-apoptotic (Bcl-2), compared to treatment with either calcitriol or 20% dietary soy alone[@B110]. A significant enhancement was also observed in the combination treated group in the up-regulation of the expression of the prostaglandin G-degrading enzyme 15-PGDH. However, the combination had the potential to increase the risk of hypercalcemia as indicated by elevated expression of intestinal calcium absorption genes (TRPV6, calbindin-9k)[@B110]. Laboratory studies have also indicated that calcitriol and dietary omega 3-polyunsaturated fatty acids act synergistically to inhibit the growth of the high passage androgen-independent PCa cell line, LNCaP-c115 at the level of the G1/S-phase transition and cell division[@B50]. The combination of vitamin A and vitamin D synergistically reduced cell viability, expression of cyclin D1 and induced apoptosis by enhancing Bax protein expression[@B111].

The combination of cetuximab, which is an anti-epidermal growth-factor receptor antibody, with calcitriol efficiently, suppressed hormone-resistant DU145 PCa cell growth. The combination inhibited DU145 cell proliferation, caused considerable cell-cycle arrest in the Go/Gal-phase and enhanced apoptosis[@B49]. The combined effect of calcitriol (10 nM) with ibuprofen, a well-known non-steroidal anti-inflammatory drug (NSAID) on LNCaP PCa cells was enhanced in vitro. This effect was found only to be additive. However, significant synergistic cell growth inhibition was achieved by combined treatment of calcitriol and ibuprofen in DHT-stimulated LNCaP cells. This combined treatment was effective in decreasing the cell transition from G1- to S-phase and enhanced apoptosis compared with the effect of single drugs[@B102]. Neither calcitriol (1-10 nM) nor liarozole (1-10 mM) had any effect on DU145 cell viability when used alone. However, 10 nM calcitriol plus 1 mM liarozole acted synergistically and significantly reduced cell viability. Liarozole induced considerable increase in calcitriol half-life from 11 to 31 h. It also enhanced calcitriol activity by potentiating its ability to up-regulate VDR protein compared with the effects of either drug alone. The mechanism of interaction is due to the ability of liarozole to inhibit CYP24A1activity, thus increasing calcitriol half-life and effect[@B81].

Sodium butyrate and trichostatin A are inhibitors of histone deacetylases activity, which acted synergistically with calcitriol radio biologically combination on DU-145 PCa cells by enhancing apoptosis[@B112]. Moreover, in vitro calcitriol acted synergistically with IR to inhibit the growth of the LNCaP human PCa cell line by potentiating IR-induced apoptosis. At radiobiologically relevant doses of IR, calcitriol also showed synergistic inhibition of growth of LNCaP cells. However, at higher doses of IR, the combination resulted in moderate antagonism. The results suggested that the synergistic effect could permit a reduction in the dose of radiation given clinically and thus potentially reduce treatment-related morbidity[@B113].

In general, these combinations acted on common pathways as well as on independent pathways, thus increasing overall, anticancer effect. The molecular mechanisms of this PD interaction are mediated through alterations in regulatory pathways within the prostate that change and enhance overall, anticancer effects such as the increase in cellular apoptosis demonstrated when calcitriol combined with IR therapy, paclitaxel, docetaxel, vitamin A, genistein, cetuximab, ibuprofen, sodium butyrate and trichostatin A. Moreover, the interaction was mediated via the inhibition of calcitriol metabolism, which increases the bioavailability of endogenous and exogenously administered calcitriol, thereby synergistically enhancing its anticancer effects. Up-regulation of VDR by genistein and liarozole was observed as a result of higher levels of calcitriol reaching the tumor site following increased half-life of calcitriol (Table [1](#T1){ref-type="table"}).

### Combinations which sensitize PCa cells to anticancer effects of calcitriol

Some compounds have been reported to enhance the antitumor activity of calcitriol. The combination of S179D, which is a molecular mimic of naturally phosphorylated human prolactin and calcitriol, was shown to inhibit the growth PC3 and DU145 PCa cell lines in vitro and vivo[@B24]. Beside that S179D sensitized the cells to calcitriol concentration that below the level that typically results in hypercalcemia. This effect was demonstrated to be in part mediated via the induction of cell death, increased protein expression of VDR and p21[@B24]. Androgen-independent PCa cells DU-145 and PC-3 are relatively insensitive to the anti-proliferative action of calcitriol. This is thought to be due to an increase in the calcitriol metabolism, as a result of CYP24 enzyme induction, which in turn leads to decreased anti-proliferative efficacy[@B114]. In vitro studies supporting this hypothesis include a rat kidney mitochondria assay which incorporates CYP24A1 inhibition using 2-(4-hydroxybenzyl)-6-methoxy-3, 4-dihydro-2H-naphthalen-1-one and calcitriol that led to produce a greater inhibition of proliferation in DU-145 cells compared to single agent treatments[@B114]. Examination of the regulation of VDR target gene mRNA in DU-1455 cells revealed that co-treatment of calcitriol plus inhibitor of CYP enzymes co-ordinately up-regulated CYP24, p21and GADD45alpha[@B114]. When calcitriol was combined with a CK2 inhibitor, it enhanced calcitriol-mediated antitumor effects[@B82]. The inhibition of CK2 by 5, 6, 7-tetrabromobenzimidazole, a protein kinase CK2 selective inhibitor, was also shown to inhibit CYP24A1 promoter activity induced by calcitriol in PC3 cells. Furthermore, the ability of calcitriol to induced CYP24A1 mRNA expression was reduced by using CK2 siRNA knockdown and this significantly enhanced calcitriol-mediated antiproliferative effects in vitro and vivo in a xenograft model. These observations suggested that protein kinase CK2 contributes to calcitriol mediated target gene expression and is involved in the regulation of CYP24A1 expression. To summarize, combining selected drugs with calcitriol sensitizes prostate cells to the actions of calcitriol by i) inhibiting its metabolism and ii) up-regulating VDR and its target genes, thus enhancing overall calcitriol antitumor activity.

Summary of Clinical Studies
---------------------------

### Combining calcitriol with cytotoxic agents

Although all preclinical data published so far strongly support the significance of calcitriol as an anticancer agent for prevention and/or treatment of PCa, its use as an anticancer agent alone or in combination has not yet been fully established clinically (Table [2](#T2){ref-type="table"}). A phase I clinical trial has shown that weekly dosing allows substantial dose-escalation of calcitriol, and in follow-up a phase II trial suggested that adding weekly high-dose calcitriol may enhance the activity of weekly docetaxel in patients with advance stage disease[@B115]. Adding DN-101, a high-dose oral formulation of calcitriol designed for cancer therapy, to docetaxel treatment significantly enhanced the reduction in serum PSA levels in response to docetaxel. The use of high oral calcitriol combined weekly with docetaxel for the treatment of metastatic androgen-independent PCa (AIPCa) patients was recognised as safe and generally well tolerated compared with the toxicity related complications experienced with single-agent docetaxel treatment[@B55],[@B115]-[@B122]. Metastatic AIPCa patients were treated with 60 µg calcitriol orally in a combination with estramustine and docetaxel every 21 days for up to 12 cycles. High dose calcitriol (60 µg daily) appeared to be safe when added to this chemotherapeutic regimen and was well tolerated[@B123]. When CRPCa patients were given high weekly doses of calcitriol (0.5 µg/kg orally), in combination with docetaxel and zoledronic acid, half of the patients had a PSA response and this regimen was also well tolerated[@B117]. In addition, the pharmacokinetics of either calcitriol or docetaxel was not affected by the presence of its companion drug. In an exploratory substudy, PSA and measurable disease response rates as well as time to progression and survival were also promising when compared with phase II studies reported in the literature for single-agent docetaxel for the same patient population[@B120]. High dose oral calcitriol (0.5 µg/kg) used in combination with intravenous carboplatin in patients with metastatic AIPCa was not associated with an increase in the response rate compared with the reported activity for carboplatin alone[@B122]. The outcomes were similar to that expected with single-agent carboplatin with only one of seventeen patients in the study achieving a confirmed PSA declined response and no patient achieved the palliative response end point (2-point reduction or normalization of pain on the present pain intensity scale without increased analgesic consumption[@B53] **(Table [2](#T2){ref-type="table"})**.

### Combining calcitriol with corticosteroids and NSAID

One year of dosing with weekly calcitriol and daily naproxen treatment to 21 patients with PCa relapse was well tolerated by most patients and effective in delaying PCa growth and progression according to a reduction in PSA doubling time which was achieved in 75% of patients. High-dose intermittent calcitriol plus dexamethasone appears to be safe, feasible, and also demonstrated antitumor activity[@B26],[@B124],[@B125]. The combination effect of the daily calcitriol, dexamethasone and carboplatin in thirty-four patients with HRPCa also produced a PSA response in 13 of 34 patients. PSA was decreased in 13 treated patients, and the median overall survival was 97.7 weeks. However, significant side effects were reported[@B121]. The combination of intermittent high doses (8, 10 and 12 µg) calcitriol plus dexamethasone in 43 patients with AIPCa caused slight PSA decline with minimum side effects. In this case, there was no clear evidence that combination treatment was better that dexamethasone treatment alone[@B121]. Calcitriol, dosed in a pulsatile manner, was safe and tolerated when its toxicity was examined with zoledronate and the addition of dexamethasone at the time of disease progression[@B126]. In patients with progressive PCa, adding dexamethasone to calcitriol at escalating doses from 4 µg up to 30 µg per day was well tolerated. In addition, when administered three times per week in combination with intravenous zoledronate (4 mg monthly) with or without dexamethasone. Patients tolerated therapy well, even in those patients who received higher calcitriol doses of 30 µg treatment group; a maximum tolerated dose was therefore not definable. The Cmax observed in the 24 µg and 30 µg cohorts ranged from 391 to 968 pg/mL with minimal antitumor effects observed. The Cmax in the 24 µg and 30 µg cohorts were greater than the preclinical levels associated with antitumor effects[@B127]. Conversely, adding calcitriol to mitoxantrone and prednisone in AIPCa patient did not cause any apparent enhancement of mitoxantrone toxicity[@B128]**(Table [2](#T2){ref-type="table"})**.

Conclusion
==========

Calcitriol biosynthesis and metabolism pathways are catalyzed by multiple CYP enzymes. This provides the opportunity to the researchers and clinicians to either stimulate calcitriol biosynthesis or inhibit its metabolism in an organ-specific manner, leading to higher exposure to endogenous or exogenously administered calcitriol. Similarly, targeting different biological pathways with calcitriol and currently available drugs present pharmacodynamic interactions, where the pharmacological actions of the combination are synergized or potentiated. Combination therapy with calcitriol for the treatment of PCa appears to be efficacious in vitro and vivo PCa models. However, definitive evidence regarding treatment efficacy has not yet been established clinically. Most clinical trials have taken place in patients with recurrence or castration‑resistant disease; studies should be carried out in PCa patients on active surveillance and/or receiving adjuvant therapy. Other targets of calcitriol PK and PD need to be studied, and further research is required to better explain the relationships of PCa risk with low vitamin D exposure/supplementation. In addition, from a pre-clinical perspective, a better understanding of cross talk between AR and VDR and their role in PCa growth and progression will open new avenues to explore regarding therapeutic calcitriol combination regimens. In addition, combining other therapeutic agents with calcitriol lowers required calcitriol doses at which hypercalcemic effects are no longer a concern. Overall, combinations of calcitriol with selected drugs are promising and offer a contemporary approach to maximizing the multifaceted biological and therapeutic actions of vitamin D in the context of PCa.
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![Summary of calcitriol-drug combination exerting PK/PD interactions in distinct intracellular compartments of prostate cell. Inhibitors of CYP 27A1, CYP24A1 and CYP3A4 isoform can play a vital role in maintaining the active form of vitamin D3. PK interaction outcomes can lead to significant modification of calcitriol levels in both serum and tissues. Diagram also delineates the essential cell signaling pathways for prostate cancer development and crosstalk between them. PD interaction are mediated through alterations in these regulatory pathways that enhance overall anticancer effects. CYP: Cytochrome P450; PK: Pharmacokinetic; PD: pharmacodynamic; VDBP: vitamin D-binding globulin; CDK: Cyclin-dependent kinases; P21: cyclin-dependent kinase inhibitor; S179D:a molecular mimic of naturally phosphorylated human Prolactin; NSAID: Nonsteroidal anti-inflammatory drug; KTZ; Ketoconazole; DEX::Dexamethasone; IR: Ionizing radiation; P53:Tumor protein; COX-2: cyclooxygenase-2; TBBz :4, 5, 6, 7tetrabromobenzimidazole;MMP-2: matrix metalloproteinase-2; CEACAM; carcinoembryonic antigen-related cell adhesion molecules; Pgp: multidrug resistance protein 1;EP2: prostaglandin E receptor 2; PG: prostaglandin.](jcav07p0391g002){#F2}

###### 

Summary of preclinical calcitriol combination studies for prostate cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug/Agent combined   Calcitriol dose                     Model used                                            Mechanisms\                         Pharmacological Outcomes & Comments   Ref.
                                                                                                                  PK/PD Based interaction                                                   
  --------------------- ----------------------------------- ----------------------------------------------------- ----------------------------------- ------------------------------------- -------
  Docetaxel             Pre-treatment\                      PC3                                                   ↑apoptosis\                         Sensitization\                        ^105^
                        100 nM calcitriol                                                                         ↓Bcl-2, ↑Bax, MRP mRNA\             ↓ % Cell viability\                   
                                                                                                                  and protein levels                  ↓ IC~50~                              

  Ketoconazole\         Cotreatemt\                         PC3\                                                  ↓CYP24A1 activity\                  Sensitization\                        ^114^
  +\                    10 nM calcitriol                    DU145                                                 ↑p21 mRNA\                          ↓% Cell viability                     
  Tetralone                                                                                                       ↑Calcitriol t~1/2~                                                        

  Vitamin A             Cotreatemt\                         PC3\                                                  ↑ Cyclin D1 mRNA and protein\       Sensitization\                        ^111^
                        10 nM calcitriol                    LNCaP\                                                Bax mRNA and protein                ↓ % Cell viability                    
                                                            DU145                                                                                                                           

  Genistein             Cotreatemt\                         HPEC\                                                 ↑G(2)M arrest and\                  Synergistically\                      ^109^
                        10 nM calcitriol                    LNCaP                                                 G(1/0) arrest                       ↓ % Cell viability                    

  Ketoconazole\         Pre-treatment\                      PC3\                                                  ↓CYP24A1 activity\                  Synergistically\                      ^51^
  +\                    5 µM calcitriol\                    PC3 prostate\                                         ↑apoptosis\                         ↓ % Cell viability\                   
  Dexamethasone         for 24hr\                           tumor xenograft\                                      ↑Caspase 8 activation\              Synergistically\                      
                        calcitriol alone IP (31.25μg/kg)\   mouse model                                           ↓CYP24A1 activity\                  ↓Tumor growth                         
                        (QD, twice, weekly)                                                                       ↓PC3 tumor growth\                                                        
                                                                                                                  ↓Ki-67\                                                                   
                                                                                                                  ↑Apoptosis ↑, caspase-3                                                   

  Paclitaxel            Pre-treatment\                      PC3\                                                  ↑p21 protein levels\                Synergistically\                      ^104^
                        5 µM calcitriol\                    PC3 prostate tumor\                                   ↓cdk1 protein levels\               ↓Tumor growth\                        
                        for 24 hr.\                         xenograft mouse model                                 ↑p21 protein levels\                Synergistically\                      
                        Pre-treatment\                                                                            ↓cdk1 protein levels                ↓Tumor growth                         
                        0.75 μg I.P\                                                                                                                                                        
                        for 3 days                                                                                                                                                          

  Carboplatin           Drugs were combined\                LNCaP\                                                ↑G(2)M arrest                       Sensitization                         ^106^
                        at IC~20~                           DU145                                                                                                                           

  TBBz                  Pre-treatment\                      Transfected PC3 cells with siRNA-CK2\                 ↓CYP24A1 mRNA\                      Sensitization\                        ^82^
                        10 nM calcitriol                    PC3 prostate tumor xenograft\                         ↓CYP24A1 activity\                  ↓ % Cell viability\                   
                                                            mouse model                                           ↓Tumor CYP24A1 mRNA\                ↓Tumor volume                         
                                                                                                                  ↓Ki-67\                                                                   
                                                                                                                  ↑apoptosis ↑caspase-3 cleavage                                            

  Cryoablation          4.0 µg/kg of calcitriol\            Murine prostate tumors (RM-9) in male C57BL/6J mice   ↓Ki-67\                             Sensitization\                        ^129^
                        (intratumoral injection                                                                   ↑apoptosis\                         ↑Necrosis\                            
                                                                                                                  ↓Procaspase-9\                      ↑Apoptosis\                           
                                                                                                                  ↑Procaspase-9 cleavage\             ↓Proliferation\                       
                                                                                                                  ↑caspase-3 cleavage ↓AKT            ↓Tumor volume                         

  Sodium valproate\     Cotreatemt\                         DU145                                                 ↑DNA damage\                        Sensitization                         ^103^
  +\                    10 nM calcitriol                                                                          ↓DNA replication\                                                         
  Radiotherapy                                                                                                    S-phase cell-cycle arrest\                                                
                                                                                                                  ↑apoptosis                                                                

  S179D                 Cotreatemt\                         PC3\                                                  ↑VDR\                               Sensitization\                        ^130^
                        10 nM calcitriol                    DU145                                                 ↓P21                                ↓ % Cell viability                    

  Cetuximab             Cotreatemt\                         DU145                                                 ↓cell proliferation\                Sensitization                         ^131^
                        10 nM calcitriol                                                                          ↑apoptosis                                                                

  Fish oil              Cotreatemt\                         LNCaP-c115                                            cycle arrest at G(1)/S-phase        Synergistically                       ^132^
                        10 nM calcitriol                                                                                                                                                    

  Ibuprofen             Cotreatemt\                         LNCaP                                                 ↓Proliferation\                     Sensitization                         ^102^
                        10 nM calcitriol                                                                          cycle arrest\                                                             
                                                                                                                  ↑apoptosis                                                                

  Radiotherapy          Antagonism at high IR dose\         LNCaP                                                 ↑apoptosis                          Synergistically\                      ^113^
                        Cotreatemt\                                                                                                                   ↓LNCaP growth                         
                        10 nM calcitriol                                                                                                                                                    

  Sodium butyrate\      Cotreatemt\                         LNCaP\                                                ↑apoptosis\                         Synergistically,\                     ^112^
  +\                    10 nM calcitriol                    PC-3\                                                 ↓P21                                ↓inhibit the growth                   
  Trichostatin A                                            DU-145                                                                                                                          

  Liarozole             Cotreatemt\                         DU 145                                                ↓CYP24A1 activity\                  Synergistically\                      ^81^
                        10 nM calcitriol                                                                          ↑Calcitriol t~1/2~ (11 to 31 hr)\   ↓cell viability                       
                                                                                                                  ↑VDR activity                                                             

  Ginsenoside\          \-                                  Human\                                                CYP3A4 activity↓                    Unknown                               ^63^
  aPPD, aPPT                                                microsomal\                                                                                                                     
                                                            protein                                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PK: Pharmacokinetic; PD: pharmacodynamic; CYP: Cytochrome P450; IC~50~: The half maximal inhibitory concentration; t~1/2~:half-life; VDR: vitamin D receptor; HPEC: Primary human prostate epithelial cells; CK2: Casein kinase 2; ki67: proliferation marker; BAX: pro-apoptotic protein; Bcl2: anti-apoptotic protein; VDBP: vitamin D-binding globulin; CDK: Cyclin-dependent kinases; P21: cyclin-dependent kinase inhibitor. TBBz: 4, 5, 6, 7-tetrabromobenzimidazole; S179D is a molecular mimic of naturally phosphorylated human Prolactin; aPPT: 20(S)-protopanaxatriol; aPPD: 20(S)-protopanaxadiol.

###### 

Summary of clinical calcitriol combination studies for prostate cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug combined     Patient\                     Calcitriol Dose\                                        Clinical\                          Clinical\                                                          Comments                                                                                 Ref.
                    Type &\                      or\                                                     Endpoint                           Outcomes                                                                                                                                                    
                    size                         Formulation                                                                                                                                                                                                                                            
  ----------------- ---------------------------- ------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------- -------
  Docetaxel         AIPCa\                       calcitriol (0.5 μg/kg) weekly\                          PSA,\                              PSA ↓ n=30\                                                        This regimen was safe and well tolerated\                                                ^120^
                    37                           (Rocaltrol, Roche Pharmaceuticals,\                     Safety & Efficacy                  No different in toxicity compared to docetaxel single treatment\   Phase I                                                                                  
                                                 Basel, Switzerland)                                                                        No PK interaction                                                                                                                                           

  Docetaxel         AIPCa\                       45 µg DN-101 weekly                                     PSA\                               PSA ↓ n=145\                                                       There was an improvement in Patient survival with no an increase in toxicity             ^55^
                    250                                                                                  Survival time                      Survival time ↑                                                                                                                                             

  Docetaxel         Metastatic\                  45 µg DN-101 weekly                                     PSA\                               PSA ↓n=113\                                                        Need further investigation                                                               ^116^
                    AIPCa\                                                                               Clinical progress\                 PSA ↔ n=113\                                                                                                                                                
                    250                                                                                  Safety & Efficacy                  Progress n=24                                                                                                                                               

  Docetaxel\        CRPC\                        Calcitriol\                                             Safely& efficacy\                  PSA ↓n=23\                                                         This regimen shows a significant different, safe and well tolerated                      ^117^
  +\                30                           (0.5 µg/kg orally in 4 divided doses over 4 h )         Toxicity                           Survival time ↑                                                                                                                                             
  Zoledronic acid                                                                                                                                                                                                                                                                                       

  Estramustine\     metastatic\                  High dose calcitriol 60 μg orally                       Safety &\                          Asymptomatic hypercalcemia n=4                                     High dose calcitriol may be safely added to docetaxel and Estramustine administered      ^123^
  +\                AIPCa\                                                                               Efficacy                                                                                                                                                                                       
  Docetaxel         24                                                                                                                                                                                                                                                                                  

  Naproxen\         Relapse\                     High dose calcitriol (DN101, Novacea)\                  Safely& efficacy                   PSA doubling time ↓ n=4\                                           Well tolerated and safe\                                                                 ^133^
  open label        21                           45 µg /week                                                                                PSA doubling time ↑\                                               75% responded to the treatment regimen\                                                  
                                                                                                                                            n=14                                                               phase II                                                                                 

  Dexamethasone     CRPCa\                       i.v 74 μg weekly                                        PSA\                               No patient had response\                                           Clinical trial response failed\                                                          ^125^
                    18                                                                                   RECIST                             Progress n=14\                                                     Phase II                                                                                 
                                                                                                                                            Toxicity n=7                                                                                                                                                

  Dexamethasone\    HRPC\                        0.5 µg daily                                            PSA                                PSA ↓ n=13\                                                        This regimen has shown a good response with an acceptable side effect profile compare\   ^121^
  +\                34                                                                                                                      Significant adverse events                                         Phase II                                                                                 
  Carboplatin                                                                                                                                                                                                                                                                                           

  Dexamethasone     43\                          Intermittent high different doses of 8, 10 and 12 μg\   Toxicity                           Partial PSA↓ n=8\                                                  No clear different and superior to dexamethasone treatment alone\                        ^124^
                    AIPCa                        3 times a week for a month\                                                                Toxicity was low                                                   Calcitriol at high dose was safe, feasible, and had antitumor effects\                   
                                                 (Rocaltrol, Roche Pharmaceuticals, Indianapolis, IN)                                                                                                          Calcitriol was administered a month prior to dexamethasone dosing\                       
                                                                                                                                                                                                               Phase II                                                                                 

  Dexamethasone\    Metastatic\                  45 µg DN-101                                            Overall survival (OS), assessed\   Shorter survival than the control                                  Clinical trial response failed. This failure might be\                                   ^134^
  +\                CRPC\                                                                                By the Kaplan-Meier method.                                                                           due to either docetaxel regime or calcitriol dose\                                       
  Prednisolone\     953                                                                                                                                                                                        Randomized, Open-Label Phase III Trial                                                   
  +\                                                                                                                                                                                                                                                                                                    
  Docetaxel                                                                                                                                                                                                                                                                                             

  Carboplatin       metastatic AIPCa patients\   (0.5 µg/kg)\                                            PSA\                               PSA↓ n=1\                                                          No different compare to single agent\                                                    ^122^
                    17                           repeated dose every 4 weeks                             Palliative response                Partially PSA↓ n=4\                                                No dose related toxicity\                                                                
                                                                                                                                            Pain reduction n=3                                                 This might be due to low dose of calcitriol given                                        

  Mitoxantrone\     19\                          Calcitriol ((DN-101)\                                   PSA decline to half\               PSA↓ n=5\                                                          This might be due to low dose of calcitriol given                                        ^128^
  +\                metastatic\                  180 µg orally\                                          Quality of life\                   No different in Toxicity\                                                                                                                                   
  Prednisone\       AIPCa patient                Every 3 weeks                                           was evaluated                      physical functioning↓\                                                                                                                                      
  Phase II                                                                                                                                  fatigue, insomnia, and\                                                                                                                                     
                                                                                                                                            diarrhea↑                                                                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: Randomized control trial; HRPC: Hormone-refractory prostate cancer; CRPS: AIPCa: Androgen independent prostate cancer; RECIST: Response Evaluation Criteria in Solid Tumors; PSA: Prostate cancer antigen; IV: Intravenous; PK: Pharmacokinetics; Ref: References; CRPCa: Castration-resistant prostate cancer; DN-101: a high-dose (15 μg) formulation of calcitriol.
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